State-of-the-art strategies for immunosuppression

Current Opinion in Organ Transplantation

Volumn 12, Issue 5, 2007, Pages 536-542

  Jessup, Mariell ^a,b   Brozena, Susan C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Heart Failure/Transplant Program   (United States)

Author keywords

Heart transplantation; Immunosuppression; Rejection

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; AVASCULAR NECROSIS; CARDIAC GRAFT REJECTION; CATARACTOGENESIS; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONVULSION; CUSHINGOID SYNDROME; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; HEADACHE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; LEUKOPENIA; LIFESPAN; LIMB PARESTHESIA; MONOTHERAPY; NEPHROTOXICITY; NEUROPATHY; OBESITY; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PEPTIC ULCER; PERSONALITY DISORDER; POSTOPERATIVE INFECTION; REVIEW; RISK; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 34648858611     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282efe007     Document Type: Review

References (47)

1. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006; 25:1063-1069.
2. Uber PA, Mehra MR. Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant 2007; 26:205-209.
3. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514-1516.
4. Batiuk TD, Barry JM, Bennett WM, et al. Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants. Transplant Proc 1993; 25 (1 Pt 2):1391.
5. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006; 81:1542-1548. An important study comparing an older induction therapy with a newer approach.
6. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352:2705-2713.
7. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24:1297-1304.
8. Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit antithymocyte globulin for prophylaxis of acute rejection after heart transplantation: a noninferiority trial. J Heart Lung Transplant 2007; 26:258-263.
9. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004; 110:3858-3865.
10. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006; 6:1387-1397.
11. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434-439. A critical study that compared the calcineurin inhibitors.
12. Ray JE, Keogh AM, McLachlan AJ. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring. J Heart Lung Transplant 2006; 25:1223-1229.
13. Delgado DH, Rao V, Hamel J, et al. Monitoring of cyclosporine 2-h postdose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 2005; 24:1343-1346.
14. Solari SG, Goldberg LR, DeNofrio D, Shaw LM. Cyclosporine monitoring with 2-h postdose levels in heart transplant recipients. Ther Drug Monit 2005; 27:417-421.
15. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858.
16. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694-2700.
17. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-1386. A critical study that explored the optimal combination of drugs in maintenance immunosuppression.
18. Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005; 24:1863-1867.
19. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26:250-257.
20. Rothenburger M, Zuckermann A, Bara C, et al., Certican Consensus Study G. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007; 26:305-311.
21. Taylor DO, Edwards LB, Boucek MM, et al., International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report - 2006. J Heart Lung Transplant 2006; 25:869-879.
22. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24:945-955.
23. Jarcho J, Naftel DC, Shroyer TW, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:583-595.
24. Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1995; 14:409-418.
25. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710-1720.
26. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6:150-160. This paper reviews the results of a multicenter trial of gene expression profiling to detect the absence of moderate to severe rejection, thereby identifying a group of patients who are at low risk for rejection.
27. Starling RC, Pham M, Valantine H, et al., Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 2006; 25:1389-1395.
28. Uber WE, Uber LA, VanBakel AB, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc 2004; 36:3245-3249.
29. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004; 110:3734-3740.
30. Costanzo MR, Koch DM, Fisher SG, et al. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 1997; 16:169-178.
31. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339:1744-1751.
32. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006; 25:283-288.
33. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004; 19:166-169.
34. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58-69.
35. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Semin Immunopathol 2003; 25:119-140.
36. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006; 25:1277-1282.
37. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80:1019-1025.
38. Drakos SG, Kfoury AG, Long JW, et al. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg 2006; 82:889-893.
39. Gonzalez-Stawinski GV, Cook DJ, Chang AS, et al. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. J Heart Lung Transplant 2006; 25:613-618.
40. Joyce DL, Southard RE, Torre-Amione G, et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on posttransplant outcomes. J Heart Lung Transplant 2005; 24:2054-2059.
41. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibodymediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033-1041.
42. Reed EF, Demetris AJ, Hammond E, et al., International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153-159. This is a summary of the findings and recommendation of the International Society of Heart and Lung Transplantation-sponsored Immunopathology Task Force subcommittee. It is an excellent review of the diagnostic criteria for acute AMR.
43. Hammond ME, Stehlik J, Snow G, et al., Utah Transplant Affiliated Hospitals Cardiac Transplant Program. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3170 biopsies. J Heart Lung Transplant 2005; 24:2015-2021.
44. Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005; 5:2560-2564.
45. Veiga Barreiro A, Crespo Leiro M, Domenech Garcia N, et al. Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: incidence and management. Transplant Proc 2004; 36:778-779.
46. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24:1337-1342.
47. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001; 20:316-321.